Northern Capital Management (Washington)’s Biogen BIIB Stock Holding History

Northern Capital Management (Washington)’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-947	Closed	-$220K	–	42
2024 Q2	$220K	Hold	947	–	–	0.15%	35
2024 Q1	$204K	Hold	947	–	–	0.14%	37
2023 Q4	$245K	Hold	947	–	–	0.22%	26
2023 Q3	$243K	Hold	947	–	–	0.23%	31
2023 Q2	$270K	Hold	947	–	–	0.21%	35
2023 Q1	$263K	Hold	947	–	–	0.23%	33
2022 Q4	$262K	Hold	947	–	–	0.25%	34
2022 Q3	$253K	Buy	+947	New	+$201K	0.26%	29
2022 Q1	–	Sell	-947	Closed	-$227K	–	43
2021 Q4	$227K	Hold	947	–	–	0.18%	39
2021 Q3	$268K	Hold	947	–	–	0.23%	34
2021 Q2	$328K	Hold	947	–	–	0.28%	30
2021 Q1	$265K	Hold	947	–	–	0.24%	36
2020 Q4	$232K	Buy	+947	New	+$244K	0.23%	37

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Capital Management (Washington)'s BIIB Position: Q3 2024 in Review

Northern Capital Management (Washington) sold out of Biogen (BIIB) in Q3 2024, closing a stake of 947 shares — an estimated $220K sold.

Northern Capital Management (Washington) first reported a position in BIIB in Q4 2020 and held it in 13 quarters. The position peaked at $328K in Q2 2021. 916 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

Northern Capital Management (Washington) reported no remaining Biogen position as of Q3 2024 after selling out during the quarter.
Northern Capital Management (Washington) sold 947 Biogen shares in Q3 2024, an estimated $220K.
Northern Capital Management (Washington) first reported a position in Biogen in Q4 2020 and held it in 13 quarters.
Northern Capital Management (Washington)'s Biogen position peaked at $328K in Q2 2021.
916 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on Northern Capital Management (Washington)'s 13F filing for Q3 2024, filed 12 Nov 2024.